Trigyn Technologies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
TRIGYN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Trigyn Technologies' Board approved its unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). On a consolidated basis, revenue from operations fell to Rs. 22,449.99 lakhs from Rs. 24,194.44 lakhs in Q1 FY25, a decline of about 7%. The company swung to a consolidated net loss of Rs. 460.86 lakhs from a profit of Rs. 761.38 lakhs a year ago, while standalone results showed a loss of Rs. 499.02 lakhs. Other expenses rose sharply (Rs. 10,640.39 lakhs vs Rs. 8,930.77 lakhs), including an additional ECL (expected credit loss) provision of Rs. 2.72 crores, taking cumulative provisions on receivables to Rs. 55.27 crores. Prior period figures were restated to classify a foreign subsidiary (TTS Schweiz) as a discontinued operation. The Board also approved a leadership change — Mrs. Bhavana Rao Potluri was redesignated as Executive Vice Chair — and gave the go-ahead to set up a step-down wholly owned subsidiary in Dubai.
Negative quarter for shareholders: revenue shrank, the company moved from profit to loss, and several legacy issues (Rs. 80 crore unbooked Andhra Pradesh project revenue, Rs. 9.08 crore GST demand, Rs. 3.14 crore tax demand, and negative net worth at two subsidiaries) remain unresolved. The Dubai expansion is a long-term strategic move but unlikely to provide near-term relief; expect pressure on the stock given the weak earnings print and ongoing concerns flagged in the auditor's review.